Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
28 hedge funds and large institutions have $2.71M invested in Regulus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
11% more capital invested
Capital invested by funds: $2.44M → $2.71M (+$270K)
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.53% less ownership
Funds ownership: 3% → 2.47% (-0.53%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$126K |
| 2 |
VF
Virtu Financial
New York
|
+$72.4K |
| 3 |
Jane Street
New York
|
+$68.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.7K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$197K |
| 2 |
Bank of New York Mellon
New York
|
-$25K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$21K |
| 4 |
Two Sigma Investments
New York
|
-$21K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10K |
RGLS Hedge Fund Activity: Q1 2019 in Review
28 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2019, worth a combined $2.71M — up 11% from $2.44M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RGLS positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $126K. The largest seller was Vanguard Group, cutting an estimated $197K.
- 28 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2019, up from 27 in Q4 2018.
- Funds reported $2.71M of Regulus Therapeutics stock for Q1 2019, up 11% quarter-over-quarter.
- 8 funds opened new Regulus Therapeutics positions in Q1 2019 and 7 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $126K added.
- The largest Regulus Therapeutics seller in Q1 2019 was Vanguard Group, an estimated $197K sold.
Based on aggregated 13F filings for Q1 2019.